• Receives initial $3.0m tranche, with further $2.9m and up to $7.9m conditionally approved
• Funding to support ongoing XanaMIA phase 2b/3 Alzheimer's trial and general working capital
• Strengthens balance sheet as company progresses towards key milestones

Actinogen Medical has announced that it has received an initial tranche of $3.0m in non-dilutive funding from Endpoints Capital, with conditional commitments for a further $2.9m to be made available next quarter in relation to the final full year FY25 R&D Tax Incentive (RDTI), and up to $7.9m conditionally approved against the forecast FY26 RDTI. The total funding package of up to $13.8m will be used to support the ongoing XanaMIA phase 2b/3 Alzheimer's disease trial, as well as for general working capital. The initial $3.0m tranche, combined with $13.4m in existing funds, brings Actinogen's year-end cash balance to an estimated $16.4m. The loan is secured against the FY25 RDTI, with repayment due concurrent with receipt of the rebate anticipated later in 2025, and interest charged at commercial rates. Actinogen's CFO stated that the non-dilutive funding package is an endorsement of the robustness of the company's program, and further strengthens its balance sheet as it progresses towards important milestones, including the upcoming interim analysis for the Alzheimer's phase 2b/3 trial.